Cytosorbents Crp Asset Resilience Ratio
Cytosorbents Crp asset resilience ratio. Cytosorbents Crp (CTSO) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CTSO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cytosorbents Crp (2008–2017)
Asset resilience ratio of Cytosorbents Crp from 2008 to 2017. This chart shows how Cytosorbents Crp's Asset Resilience Ratio has changed over time. Read Cytosorbents Crp (CTSO) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cytosorbents Crp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cytosorbents Crp asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cytosorbents Crp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cytosorbents Crp Industry Peers by Asset Resilience Ratio
Compare Cytosorbents Crp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
T&L Co. Ltd
KQ:340570 |
Medical Devices | 26.03% |
|
Paxman AB
ST:PAX |
Medical Devices | -3.83% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
|
Pulsenmore Ltd
TA:PULS |
Medical Devices | 51.61% |
|
Geratherm Medical AG
XETRA:GME |
Medical Devices | 34.89% |
Cytosorbents Crp Asset Resilience Ratio by Year (2008–2017)
Cytosorbents Crp asset resilience ratio by year from 2008 to 2017. The table below shows the annual Asset Resilience Ratio data for Cytosorbents Crp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $24.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $9.69 Million | -- |
| 2015-12-31 | 19.48% | $2.19 Million | $11.25 Million | -3.49pp |
| 2014-12-31 | 22.97% | $1.95 Million | $8.47 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $4.05 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.34 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.12 Million | -- |
| 2009-12-31 | 8.92% | $199.61K | $2.24 Million | +3.02pp |
| 2008-12-31 | 5.89% | $199.61K | $3.39 Million | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more